scholarly journals Optimal cut-off score of the Edinburgh Postnatal Depression Scale for major depressive episode during pregnancy in Japan

2017 ◽  
Vol 71 (12) ◽  
pp. 836-842 ◽  
Author(s):  
Kentaro Usuda ◽  
Daisuke Nishi ◽  
Emi Okazaki ◽  
Miyuki Makino ◽  
Yo Sano
Keyword(s):  
Depressive Episode ◽  
Postnatal Depression ◽  
Major Depressive Episode ◽  
Edinburgh Postnatal Depression Scale ◽  
Depression Scale ◽  
Major Depressive

scholarly journals Validation of the Edinburgh postnatal depression scale (EPDS) for screening of major depressive episode among adults from the general population

2014 ◽  
Vol 14 (1) ◽  
Author(s):  
Alicia Matijasevich ◽  
Tiago N Munhoz ◽  
Beatriz Franck Tavares ◽  
Ana Paula Pereira Neto Barbosa ◽  
Diego Mello da Silva ◽  
...  
Keyword(s):  
General Population ◽  
Depressive Episode ◽  
Postnatal Depression ◽  
Major Depressive Episode ◽  
Edinburgh Postnatal Depression Scale ◽  
Depression Scale ◽  
Major Depressive

scholarly journals Diagnosis Accuracy of Baptista Depression Scale: Adult and Screening Versions

2021 ◽  
Vol 37 ◽  
Author(s):  
André Pereira Gonçalves ◽  
Makilim Nunes Baptista ◽  
Anna Elisa de Villemor-Amaral ◽  
Lucas de Francisco Carvalho
Keyword(s):  
Major Depressive Disorder ◽  
Depressive Disorder ◽  
Diagnostic Accuracy ◽  
Depressive Episode ◽  
Major Depressive Episode ◽  
Depression Scale ◽  
Major Depressive ◽  
Diagnosis Accuracy

Abstract This study aimed to investigate the diagnostic accuracy of the Baptista Depression Scale adult and screening versions (EBADEP-A and EBADEP-screening) for discrimination of people with a major depressive episode (MDE) or major depressive disorder (MDD) and to compare discriminative capacities. Participants were 187 people, 52 patients, and 135 non-clinical individuals. Results indicated sensitivity equal to 0.92 and specificity equal to 0.88 for EBADEP-A (cut-off = 54), and 0.96 and 0.82, respectively, for EBADEP-screening (cut-off = 17). Findings suggest equivalence between the two versions of EBADEP to discriminate people with MDE or MDD. Results indicate that the two versions can provide a correct diagnostic indicative for MDE and MDD.

Psychomotor retardation in depression, a pilot study

1991 ◽  
Vol 3 (2) ◽  
pp. 22-25
Author(s):  
J.J.M. van Hoof ◽  
L.P. van Bavel ◽  
A.J.M. van den Berg
Keyword(s):  
Depressive Episode ◽  
Major Depressive Episode ◽  
Rating Scale ◽  
Psychiatric Patients ◽  
Depression Scale ◽  
Psychomotor Retardation ◽  
Point Of View ◽  
Major Depressive ◽  
Important Sign ◽  
Depressive Patients

SummarySeveral studies have demonstrated that psychomotor retardation is an important sign of the major depressive episode, both from a diagnostic point of view and as a predictor of treatment outcome. However, it is uncertain to what extent psychomotor retardation is specific for the major depressive episode. A heterogeneous group of psychiatric patients (n=26) was studied using a rating scale developed specifically to assess psychomotor retardation (RRS). The 13 patients suffering from a major depressive episode had a significantly higher RRS score than patients with another diagnosis. Furthermore, in the depressive subjects the severity of the depression (measured by means of Hamilton's depression rating scale) appeared to correlate with the severity of the psychomotor retardation. Cognitive features of psychomotor retardation were mainly responsible for the more severe psychomotor retardation in the depressive patients. Surprisingly. Hamilton's depression scale which was used in this study does not pay much attention to these aspects.

Depressive symptoms in chronic schizophrenia patients: any differences between patients with and without a major depressive episode?

2003 ◽  
Vol 18 (3) ◽  
pp. 137-139 ◽  
Author(s):  
Yasuhiro Kaneda
Keyword(s):  
Depressive Symptoms ◽  
Depressive Episode ◽  
Major Depressive Episode ◽  
Depression Scale ◽  
Chronic Schizophrenia ◽  
Depression Score ◽  
Major Depressive

AbstractThe author investigated the differences between schizophrenia patients with and without a major depressive episode (MDE) using the Japanese Calgary Depression Scale for Schizophrenics. The total depression score was correlated with the dosage of antipsychotics in patients without an MDE, but such a correlation was not found in patients with an MDE.

FC10-01 - Pharmacogenetic association between 5HTT/SLC6A4, 5HTR2A and THP2 genes and the response to tianeptine in major depressive episode

2011 ◽  
Vol 26 (S2) ◽  
pp. 1864-1864
Author(s):  
N. Ramoz ◽  
E. Burgess ◽  
Y. Le Strat ◽  
P. Gorwood
Keyword(s):  
Treatment Response ◽  
Depressive Episode ◽  
Serotonin Receptor ◽  
Major Depressive Episode ◽  
Tryptophan Hydroxylase ◽  
Saliva Sample ◽  
Antidepressant Drug ◽  
Depression Scale ◽  
Taqman Assay ◽  
Major Depressive

IntroductionDepression is the most frequent psychiatric disorder. Antidepressant drug treatment response is modulated by genetic factors. Tianeptine molecule does not inhibit serotonin reuptake. Possible targets to this treatment are the serotonin transporter (5HTT/SLC6A4), the serotonin receptor 2A (5HT2A) and, the neuronal-specific enzyme that controls brain serotonin synthesis, the tryptophan hydroxylase-2 (TPH2).ObjectivesWe screened variants of candidate genes 5HTT/SLC6A4, 5HTR2A and THP2 in 3500 outpatients treated with tianeptine for a major depressive episode (MDE) to search for an association to a positive treatment response.AimsThe goal of this work was to study the pharmacogenetic response to tianeptine treatment in MDE.MethodsA total of 3500 outpatients were treated with tianeptine for a MDE. The criteria for a MDE were examined by the clinicians according to the DSM-IV diagnosis and the duration of each symptom was recorded during the inclusion and at 4 to 8 weeks of treatment. The Hospital Anxiety and Depression Scale (HAD) was evaluated at the two visits. DNA was extract from saliva sample and genotyping of single nucleotide polymorphisms (SNPs) was performed by Taqman assay.ResultsAll clinical and genotype data were collected for 1855 tianeptine-treated patients. The SNP rs6354 in SLC6A4 gene was significantly associated with response to tianeptine (p = 0.009; Odds ratio = 1.26; 95% confident interval = 1.06–1.50). Two SNPs in 5HT2A and one in TPH2 were also associated to treatment response (rs7322347 p = 0.03, rs7997012 p = 0.04 and rs7955501 p = 0.04).ConclusionsWe detected a pharmacogenetic association between serotonin genes and the response to tianeptine in major depressive episode.

Sign in / Sign up

Export Citation Format

Share Document